JP2021506794A5 - - Google Patents

Download PDF

Info

Publication number
JP2021506794A5
JP2021506794A5 JP2020532629A JP2020532629A JP2021506794A5 JP 2021506794 A5 JP2021506794 A5 JP 2021506794A5 JP 2020532629 A JP2020532629 A JP 2020532629A JP 2020532629 A JP2020532629 A JP 2020532629A JP 2021506794 A5 JP2021506794 A5 JP 2021506794A5
Authority
JP
Japan
Prior art keywords
seq
composition
peptide
nos
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020532629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506794A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/065545 external-priority patent/WO2019118779A2/en
Publication of JP2021506794A publication Critical patent/JP2021506794A/ja
Publication of JP2021506794A5 publication Critical patent/JP2021506794A5/ja
Priority to JP2023195583A priority Critical patent/JP2024026109A/ja
Pending legal-status Critical Current

Links

JP2020532629A 2017-12-13 2018-12-13 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤 Pending JP2021506794A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023195583A JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762598067P 2017-12-13 2017-12-13
US62/598,067 2017-12-13
PCT/US2018/065545 WO2019118779A2 (en) 2017-12-13 2018-12-13 Peptides and other agents for treating pain and increasing pain sensitivity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023195583A Division JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Publications (2)

Publication Number Publication Date
JP2021506794A JP2021506794A (ja) 2021-02-22
JP2021506794A5 true JP2021506794A5 (https=) 2022-01-06

Family

ID=66820711

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020532629A Pending JP2021506794A (ja) 2017-12-13 2018-12-13 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤
JP2023195583A Pending JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023195583A Pending JP2024026109A (ja) 2017-12-13 2023-11-17 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤

Country Status (8)

Country Link
US (3) US11535649B2 (https=)
EP (1) EP3723781B1 (https=)
JP (2) JP2021506794A (https=)
CN (1) CN111712252A (https=)
AU (1) AU2018383669B2 (https=)
CA (1) CA3085576A1 (https=)
IL (1) IL275340A (https=)
WO (1) WO2019118779A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712252A (zh) * 2017-12-13 2020-09-25 纽约州立大学研究基金会 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂
WO2021072392A1 (en) * 2019-10-10 2021-04-15 The Research Foundation For The State University Of New York Analgesic and anesthetic peptides and other agents
WO2022193185A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New conjugates
WO2025102083A1 (en) * 2023-11-12 2025-05-15 The Research Foundation For The State University Of New York Compositions and methods for treating pain or for increasing pain sensitivity
WO2025123001A1 (en) * 2023-12-08 2025-06-12 Washington University Targeted protein degradation compositions and methods of use thereof for pain control

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187533B1 (en) * 1996-09-10 2001-02-13 Arch Development Corporation Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (α), HNF1β and HNF4α
HUP0200575A3 (en) * 1999-03-25 2004-11-29 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
DE1252330T1 (de) 1999-11-26 2003-11-27 Mcgill University, Montreal Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie
US20030216310A1 (en) 2001-05-25 2003-11-20 Thornton Michael B. Transporters and ion channels
US20090087436A1 (en) 2001-07-13 2009-04-02 Myriad Genetics, Incorporated Compositions and methods for treating diseases
WO2004045535A2 (en) 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
CA2462732A1 (en) * 2001-10-01 2003-04-10 Buck Institute Target assisted iterative screening (tais) : a novel screening format for large molecular repertoires
US20040101874A1 (en) 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
BRPI0417531A (pt) 2003-12-12 2007-03-20 Wyeth Corp canal de sódio
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
WO2005118614A1 (en) * 2004-04-08 2005-12-15 Avigen, Inc. Methods and compositions for treating neuropathic pain
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
EP1904630A4 (en) 2005-06-16 2009-10-21 Bionomics Ltd METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
AU2008261951A1 (en) 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
WO2009006555A2 (en) 2007-07-02 2009-01-08 Yu, Ming Methods, composition, targets for combinational cancer treatments
US20090118301A1 (en) 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
CN102088990A (zh) 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
EP2334379A2 (en) 2008-09-26 2011-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
EP2275545A1 (en) 2009-07-16 2011-01-19 Julius-Maximilians-Universität Würzburg Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis
US8575112B2 (en) * 2009-09-18 2013-11-05 University Of Houston System Small peptide modulators of potassium channel trafficking
US9279003B2 (en) * 2010-07-07 2016-03-08 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
JP5998131B2 (ja) 2010-07-14 2016-09-28 カッパーアールエヌエー,インコーポレイテッド Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
ES2655112T3 (es) 2010-08-12 2018-02-16 Nono Inc. Tratamiento de una lesión penetrante en el cerebro
US9765115B2 (en) 2011-04-01 2017-09-19 Board of Supervisors of Louisiana State University acting on behalf of the University of Louisiana at Monroe Inhibitors of metastasis, methods of generating such inhibitors and their therapeutic applications
EP2773366B1 (en) * 2011-11-04 2017-03-01 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
EP3419621A4 (en) * 2016-02-26 2019-10-30 The Johns Hopkins University PHARMACOLOGICAL MODULATORS OF NAV1.1 VOLTAGE-CONTROLLED SODIUM CHANNELS ASSOCIATED WITH MECHANICAL PAIN
CN111712252A (zh) * 2017-12-13 2020-09-25 纽约州立大学研究基金会 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂

Similar Documents

Publication Publication Date Title
JP2021506794A5 (https=)
Garden Epigenetics and the modulation of neuroinflammation
Song et al. Th17 differentiation and their pro-inflammation function
Fu et al. Interleukin-17A contributes to the development of post-operative atrial fibrillation by regulating inflammation and fibrosis in rats with sterile pericarditis
Shi et al. MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model
JP2016517434A5 (https=)
PY2089159A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
JP2024026109A5 (https=)
PY2157405A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
JP2019529541A5 (https=)
Zhang et al. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells
JP2011518168A5 (https=)
JP2011515357A5 (https=)
MX2022006214A (es) Composiciones y métodos para desreprimir genes diana del factor de transcripción silenciador de re1.
Ververis et al. Potential non-oncological applications of histone deacetylase inhibitors
JP2024000505A5 (https=)
Clapier et al. Chromatin remodeling complexes
Katoch et al. HDAC inhibitors: applications in oncology and beyond
JP2011505798A5 (https=)
CN104168910A (zh) 肽及其用途
RU2018144784A (ru) Применение карбамата для предупреждения или лечения невралгии тройничного нерва
JP2019516722A5 (https=)
RU2008129635A (ru) Ингибиторы ссr9 активности
JP2022551467A5 (https=)
Srivastava et al. The cellular and developmental biology of medulloblastoma: current perspectives on experimental therapeutics